Celladon (La Jolla, CA), a clinical-stage biopharmaceutical company focused on cardiovascular diseases, closed a $43M Series D financing. Participants include Pfizer Venture Investments, Lundbeckfond Ventures, Novartis Venture Funds, H&Q Healthcare/Life Sciences Investors, GBS Venture Partners, Enterprise Partners Venture Capital, Johnson & Johnson Development Corporation and Venrock Associates.